Clearside Biomedical, Inc. (CLSD) Receives Average Rating of “Buy” from Brokerages

Clearside Biomedical, Inc. (NASDAQ:CLSD) has received a consensus rating of “Buy” from the eight ratings firms that are currently covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and five have issued a buy rating on the company. The average twelve-month price objective among brokers that have covered the stock in the last year is $21.25.

CLSD has been the subject of several research analyst reports. Zacks Investment Research lowered Clearside Biomedical from a “hold” rating to a “sell” rating in a research note on Friday, August 11th. Cowen and Company restated a “buy” rating on shares of Clearside Biomedical in a research note on Monday, August 7th. TheStreet lowered Clearside Biomedical from a “c-” rating to a “d” rating in a research note on Friday, August 11th. Finally, ValuEngine lowered Clearside Biomedical from a “hold” rating to a “sell” rating in a research note on Thursday, August 10th.

Clearside Biomedical (NASDAQ CLSD) opened at $7.30 on Friday. Clearside Biomedical has a 12 month low of $5.44 and a 12 month high of $24.73. The company has a debt-to-equity ratio of 0.11, a current ratio of 9.40 and a quick ratio of 9.40.

Clearside Biomedical (NASDAQ:CLSD) last released its earnings results on Wednesday, November 8th. The company reported ($0.72) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.55) by ($0.17). The business had revenue of $0.16 million during the quarter, compared to analyst estimates of $0.01 million. Clearside Biomedical had a negative net margin of 17,684.07% and a negative return on equity of 81.04%. analysts predict that Clearside Biomedical will post -2.25 EPS for the current fiscal year.

In other news, insider Daniel H. White sold 16,000 shares of the company’s stock in a transaction dated Friday, September 8th. The stock was sold at an average price of $7.57, for a total value of $121,120.00. Following the completion of the sale, the insider now owns 486,935 shares of the company’s stock, valued at $3,686,097.95. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Clay Thorp sold 24,500 shares of the company’s stock in a transaction dated Friday, September 15th. The stock was sold at an average price of $7.52, for a total value of $184,240.00. The disclosure for this sale can be found here. Insiders have sold 98,000 shares of company stock valued at $776,655 over the last 90 days. 20.90% of the stock is currently owned by insiders.

Hedge funds and other institutional investors have recently modified their holdings of the company. Nationwide Fund Advisors boosted its position in shares of Clearside Biomedical by 118.3% in the second quarter. Nationwide Fund Advisors now owns 11,703 shares of the company’s stock worth $107,000 after buying an additional 6,343 shares during the period. Citadel Advisors LLC purchased a new stake in shares of Clearside Biomedical in the second quarter worth about $117,000. Parametric Portfolio Associates LLC purchased a new stake in shares of Clearside Biomedical in the second quarter worth about $122,000. Wells Fargo & Company MN boosted its position in shares of Clearside Biomedical by 325.0% in the first quarter. Wells Fargo & Company MN now owns 16,739 shares of the company’s stock worth $133,000 after buying an additional 12,800 shares during the period. Finally, ProShare Advisors LLC boosted its position in shares of Clearside Biomedical by 4.0% in the second quarter. ProShare Advisors LLC now owns 14,814 shares of the company’s stock worth $135,000 after buying an additional 563 shares during the period. 52.56% of the stock is owned by institutional investors.

ILLEGAL ACTIVITY NOTICE: “Clearside Biomedical, Inc. (CLSD) Receives Average Rating of “Buy” from Brokerages” was originally published by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are viewing this report on another site, it was copied illegally and republished in violation of U.S. & international copyright & trademark laws. The legal version of this report can be accessed at https://www.chaffeybreeze.com/2017/11/12/clearside-biomedical-inc-clsd-receives-average-rating-of-buy-from-brokerages.html.

Clearside Biomedical Company Profile

Clearside Biomedical, Inc is a clinical biopharmaceutical company developing first-in-class drug therapies to treat blinding diseases of the eye. The Company’s product candidates focus on diseases affecting the retina, which is the tissue that lines the inside of the eye and is primarily responsible for vision, and the choroid, which is the layer adjacent to the retina that supplies the retina with blood, oxygen and nourishment.

Analyst Recommendations for Clearside Biomedical (NASDAQ:CLSD)

Receive News & Ratings for Clearside Biomedical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clearside Biomedical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply